Core Viewpoint - The Chinese cosmetics industry is projected to reach a market size of 1.1 trillion yuan, with domestic brands surpassing international brands in market share and consumer preference significantly increasing for domestic products [1][2]. Group 1: High-Quality Development and New Productive Forces - The domestic cosmetics market retail sales are expected to reach 470 billion yuan by 2025, indicating that the industry has entered a trillion-yuan market phase, with domestic brands holding a substantial market share [2][4]. - New productive forces are essential for high-quality development, transitioning the industry from traditional manufacturing to intelligent and lean production, enhancing efficiency and product consistency through automation and smart technologies [4][5]. Group 2: Intelligent Manufacturing Practices of Domestic Brands - Over the past decade, the cosmetics manufacturing industry has evolved from experience-driven to data-driven, with a clear three-stage evolution path: semi-automated, automated production lines, and now towards data-driven intelligent stages [6][8]. - Leading brands like Han Shu and Hua Xi have made significant investments in intelligent manufacturing, achieving production capacity increases and quality control improvements, with Han Shu's AI-driven production line capable of producing 2 million bottles daily [8][10]. Group 3: R&D Innovation and Cost Management - R&D expenditure rates vary by category, with skincare products averaging 1.5%-3%, while medical beauty products range from 2%-5%, indicating a differentiated investment strategy based on product type [19][20]. - Domestic brands like Shangmei and Perleya have R&D personnel ratios comparable to international brands, showcasing their commitment to innovation and development [21][22]. Group 4: International Competitiveness of Domestic Brands - Domestic brands such as Han Shu, Perleya, and Bei Tai Ni have made significant advancements in product quality, R&D innovation, and supply chain integration, enhancing their competitiveness in the global market [28][30]. - The establishment of AI-driven unmanned workshops and 5G smart factories by domestic brands demonstrates their technological capabilities and operational efficiency, positioning them among the world's best in the cosmetics industry [30].

Core Viewpoint - The Middle East beauty market is characterized by strong growth potential and consumer resilience despite ongoing geopolitical tensions, necessitating a nuanced understanding of the region's unique market dynamics [2][3]. Market Overview - The beauty and personal care market in the MENA region has surpassed $46 billion, with projections indicating double-digit growth in key segments like fragrance, hair care, and skin care from 2015 to 2027 [3]. - The changing growth logic in the global beauty market highlights the Middle East as a rare area capable of supporting both scale growth and brand premium [3]. International Beauty Groups in the Middle East - Major beauty groups are increasingly recognizing the Middle East's strategic importance, with companies like L'Oréal, Procter & Gamble, and Amorepacific reporting significant growth in the region [4][5]. - L'Oréal's market share in the Middle East has grown by 10.9%, while Amorepacific's brands have seen a remarkable 41.5% increase [4]. - Procter & Gamble's sales in the IMEA region, which includes the Middle East, contributed 5% to its annual net sales, indicating strong performance [4]. Competitive Landscape - The Middle East beauty market features four main competitors: Western brands, Korean beauty brands, local Middle Eastern brands, and emerging Chinese brands [9]. - Western brands dominate the market due to their established distribution networks and brand recognition, while Korean brands excel through product detail and localization [9][10]. - Local brands leverage cultural relevance and social media influence to connect with consumers, exemplified by brands like Huda Beauty and Moonglaze [13][15]. Challenges for Chinese Brands - Chinese beauty brands are still in the exploratory phase in the Middle East, facing challenges related to brand recognition and consumer trust [18][21]. - Successful entry into the market requires not only product quality but also effective consumer education and localized marketing strategies [21][25]. - The regulatory landscape is complex, with varying compliance requirements across different countries, making it essential for brands to navigate these regulations effectively [22][23]. Consumer Preferences and Market Dynamics - Middle Eastern consumers exhibit a strong preference for high-quality, culturally relevant products, with sensitivity to product details such as scent and texture [26]. - The market's complexity necessitates a deep understanding of local consumer behavior, which differs significantly from other regions [26]. - Brands must establish trust and credibility through compliance, effective communication, and a genuine understanding of local culture to succeed in this market [24][26].

Core Viewpoint - The Chinese cosmetics industry is projected to reach a market size of 1.1 trillion, with domestic brands surpassing international brands in market share and consumer preference significantly increasing for domestic products [1][2]. Group 1: High-Quality Development and New Productive Forces - The high-quality development of the beauty and skincare industry relies on the cultivation and implementation of new productive forces, which are essential for transitioning from traditional manufacturing to intelligent and lean production [4]. - New productive forces enhance production logic by utilizing automation and intelligent equipment to address batch fluctuations and quality control issues, thereby improving production efficiency and product consistency [4]. - These forces also align with consumer upgrade demands, facilitating product innovation that shifts from "concept marketing" to "technology empowerment" [4]. Group 2: Intelligent Manufacturing Practices of Domestic Brands - Over the past decade, the beauty and skincare manufacturing industry has transitioned from experience-driven to data-driven upgrades, establishing a clear three-stage evolution path [6]. - The current stage is characterized by intelligent data-driven systems that enable full-process traceability and flexible collaboration, meeting the industry's demands for rapid product iteration and compliance [6]. - Leading brands like Han Shu and Hua Xi have made significant investments in intelligent manufacturing, achieving production capacity increases and quality control improvements that rival international brands [10][15]. Group 3: R&D Innovation and Cost Investment - R&D expenditure rates vary across categories, with skincare products averaging 1.5%-3% and medical beauty products ranging from 2%-5%, indicating a stratified investment landscape driven by product attributes and technological barriers [19][20]. - Domestic brands like Hua Xi and Bei Tai Ni have significantly increased their R&D personnel ratios, aligning closely with international brands, showcasing their commitment to innovation and development [21][22]. - The production cost rates for various product categories range from 15% to 30%, with domestic brands leveraging self-researched technologies and integrated supply chains to maintain competitive pricing while ensuring quality [25][27]. Group 4: International Competitiveness of Domestic Brands - Domestic beauty brands, exemplified by Han Shu, Peiliya, and Bei Tai Ni, have achieved comprehensive breakthroughs in core competitiveness through new productive forces [28]. - The implementation of intelligent manufacturing has enabled micro-level quality control, establishing trust barriers in product quality [30]. - The integration of AI-driven workshops and 5G smart factories has positioned domestic brands at the forefront of technological advancement and operational efficiency, contributing to the high-quality development of China's beauty and skincare industry [30].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 50.56 [1][5]. Core Insights - The main brand, Winona, has been actively streamlining its SKU and refocusing resources on key products since the second half of 2024. There are signs of price stabilization starting mid-2025, and online GMV began to recover in Q4 2025, indicating positive results from reduced inefficient spending and product structure optimization. Cash flow has significantly improved, and there are signs of recovery in profitability [1][5][6]. - The multi-brand strategy is progressing steadily, with core sub-brands like Winona Baby and Aikeman showing high growth in online GMV since Q4 2025. The brand matrix is becoming increasingly comprehensive due to external investments [1][5][8]. Financial Performance - Revenue for the main brand Winona reached RMB 5.2 billion in 2023, but faced pressure in 2024 due to inventory adjustments and product structure changes, with revenues of RMB 4.91 billion and RMB 1.95 billion in the first half of 2024 and 2025 respectively, reflecting year-on-year declines of 5.5% and 18.4% [6][8]. - The company’s gross margin improved to 74.33% in the first three quarters of 2025, with a year-on-year increase of 0.6 percentage points, attributed to maintaining stable pricing and reducing promotional expenses [7]. - The net cash flow from operating activities for the first three quarters of 2025 was RMB 442 million, a significant increase compared to RMB 6 million in the same period of 2024 [7]. Earnings Forecast and Valuation - The company’s net profit attributable to the parent company is forecasted to be RMB 515.4 million in 2025, with an EPS of RMB 1.22. The projections for 2026 and 2027 are RMB 670.97 million (EPS of RMB 1.58) and RMB 786.7 million (EPS of RMB 1.86) respectively [4][9]. - The company is assigned a PE ratio of 32x for 2026, with a target price of RMB 50.56 based on expected revenue and profit recovery [9].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 50.56 [1][5]. Core Insights - The main brand, Winona, has been actively streamlining its SKU and focusing resources on key products since the second half of 2024. There are signs of price stabilization starting mid-2025, and online GMV began to recover in Q4 2025, indicating positive results from reduced inefficient spending and optimized product structure. Cash flow has significantly improved, and there are signs of recovery in profitability [1][5]. - The multi-brand strategy is progressing steadily, with core sub-brands like Winona Baby and Aikeman showing high growth in online GMV since Q4 2025. The brand matrix is becoming increasingly comprehensive due to external investments [1][5]. Financial Performance - Revenue for the main brand Winona reached RMB 5.2 billion in 2023, but faced pressure in 2024 due to inventory adjustments and product structure changes, with revenues of RMB 4.91 billion and RMB 1.95 billion in the first half of 2024 and 2025 respectively, reflecting year-on-year declines of 5.5% and 18.4% [6]. - The gross margin for the company was 74.33% in the first three quarters of 2025, showing a year-on-year increase of 0.6 percentage points, attributed to stable pricing strategies and reduced promotional expenses [7]. - The company’s net cash flow from operating activities was RMB 442 million in the first three quarters of 2025, compared to only RMB 6 million in the same period of 2024 [7]. Growth Projections - The company forecasts net profit attributable to the parent company for 2025, 2026, and 2027 to be RMB 515.4 million, RMB 670.97 million, and RMB 786.7 million respectively, with corresponding EPS of RMB 1.22, RMB 1.58, and RMB 1.86 [9]. - The expected revenue growth rates for 2025, 2026, and 2027 are projected at -4.47%, 12.32%, and 10.05% respectively [4]. Brand Development - Winona Baby is focusing on the sensitive skin segment for infants, achieving an online GMV of RMB 90.7 million in Q4 2025, a year-on-year increase of 21.1%. Aikeman continues to leverage its anti-aging research advantages, with online sales reaching RMB 14.5 million in Q4 2025, a staggering year-on-year increase of 736.5% [8]. - The company has been actively expanding its brand portfolio through strategic investments, including a stake in a makeup brand and a medical beauty device company, enhancing its presence in the beauty and personal care sectors [8].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting potential growth despite recent market underperformance [2][3]. Core Insights - The cosmetics and medical beauty sector has underperformed the market, with the Shenwan Beauty Care Index declining by 3.0% from February 27 to March 6, 2026. The Shenwan Cosmetics Index fell by 4.9%, while the Shenwan Personal Care Products Index decreased by 0.7% [3][4]. - Upbeauty Co., Ltd. has exceeded expectations for 2025, forecasting revenue between 9.1 billion and 9.2 billion yuan, representing a year-on-year increase of 34.0%-35.4%. The net profit attributable to shareholders is expected to be between 1.14 billion and 1.16 billion yuan, reflecting a growth of 41.9%-44.4% [9]. - The report emphasizes the importance of Upbeauty’s core anti-aging product line, which is continuously iterating to meet the upgrading trend of domestic anti-aging consumption, thereby enhancing both brand and product strength [9]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the overall market, with significant declines in key indices [3][4]. - The report notes that the Shenwan Cosmetics Index's decline of 4.9% is notably worse than the Shenwan A Index by 2.5 percentage points [4]. Company Highlights - Upbeauty Co., Ltd. is highlighted for its strong performance, with a positive earnings forecast for 2025, driven by its core business and product innovation [9]. - Huaxi Biological (688363.SH) reported a net profit of 291 million yuan for 2025, a year-on-year increase of 67.03%, indicating a successful strategic transformation [3][9]. - Yixian E-commerce reported a revenue of 4.3 billion yuan for 2025, a 26.7% increase year-on-year, marking its first annual Non-GAAP profit since its listing [22]. Market Trends - The report identifies a structural growth phase in the nutrition and health food market, with a market size reaching over 100 billion yuan, significantly outpacing traditional food sectors [11]. - The online DTC channel is recognized as a core growth engine for the industry, with companies like Xizi Health achieving over 98% of their revenue from online sales [11]. Investment Recommendations - The report recommends focusing on companies with strong channel and brand matrices, such as Upbeauty Co., Ltd. and Mao Ge Ping, which are expected to see high GMV growth [3][9]. - It also suggests monitoring companies with improving performance metrics, including Proya, Marubi, and Huaxi Biological, as well as those in the maternal and infant sector like Shengbeila and Kidswant [3].

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook for its stock performance in the near term [6]. Core Insights - The company is expanding its presence in the medical aesthetics sector, with a focus on integrating cosmetic and medical products. Recent approvals for differentiated injection products highlight the company's strategic foresight in selecting investment targets [2][6]. - The main brand, Winona, has shown improvement in its performance, particularly during the 2025 Double Eleven shopping festival, where it ranked 8th in the beauty category on Tmall, reflecting a slight increase from the previous year [2]. - The company has made significant investments in various medical aesthetic ventures, including a recent investment in Yizheng Biotechnology and ongoing collaborations with Weimai Medical to explore innovative perioperative skin care solutions [2]. Financial Summary - The company’s market capitalization is approximately 19.87 billion yuan, with a circulating market value of the same amount. The stock has seen a 52-week high of 50.85 yuan and a low of 39.34 yuan, with a price-to-earnings (P/E) ratio ranging from 32.78 to 42.38 [5]. - Profit forecasts indicate a net profit attributable to the parent company of 5.3 billion yuan in 2025, with expected growth rates of 6.3%, 24.7%, and 15.5% for the years 2025, 2026, and 2027 respectively [6][7].

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook for its stock performance in the near term [6]. Core Insights - The company's main brand is showing gradual improvement, with a focus on expanding its presence in the medical aesthetics sector, which is expected to enhance its competitive edge [2]. - The approval of a new injectable product for temporal filling marks a significant milestone, being the first of its kind globally and in China, highlighting the company's strategic investments [1]. - The main brand, Winona, has shown a recovery trend in sales, particularly during the 2025 Double Eleven shopping festival, suggesting effective adjustments in strategy and management [2][6]. Summary by Sections Company Overview - The company, Betaini, has a total market capitalization of approximately 19.87 billion yuan, with a 52-week price range of 50.85 to 39.34 yuan [5]. Financial Projections - The projected net profit for the company is expected to grow from 534.63 million yuan in 2025 to 770 million yuan in 2027, reflecting a compound annual growth rate of approximately 15.5% [6][7]. - Revenue is forecasted to increase from 5.45 billion yuan in 2025 to 6.50 billion yuan in 2027, with a notable recovery expected in 2026 [7]. Market Position - The company's stock has shown a 52-week increase of 19.22%, indicating a positive market sentiment [5]. - The main brand's ranking on Tmall has improved, suggesting a recovery in consumer confidence and brand performance [2].

Summary of Conference Call Notes Company Overview - The focus is on Beitaini, a company in the beauty and personal care industry, which has recently seen a significant stock price increase of 18.9% since January 14, 2023, following a recommendation from the research team [1] Key Points and Arguments - **Market Recognition**: Initially, the market was uncertain about the valuation of Beitaini, but it has gradually recognized the potential for a bottom reversal in the beauty sector, shifting from skepticism to seeking more investment opportunities in beauty brands [1] - **Target Valuation**: The projected target price for Beitaini in 2026 is set at 300 billion, indicating a potential upside of over 40% from the current levels [1] - **Revenue Breakdown**: The revenue estimation is based on three main components: 1. Main brand net profit margin improvement contributing 200 billion 2. Sub-brands expected to generate 50 billion 3. Medical beauty options contributing another 50 billion [1] Additional Insights - **Main Brand Focus**: The current year is seen as foundational for the main brand, with a focus on profit margin recovery. Key observation points for financial performance are set for April, August, and October [2] - **Sub-brands Contribution**: Sub-brands are anticipated to be the primary driver of revenue growth this year, with a significant contribution to market capitalization [3][4] - **High-frequency Data**: High-frequency data from sub-brands is considered more critical for stock price movement compared to the main brand [4] - **Medical Aesthetics Market**: The timing for entering the medical aesthetics market is suggested to align with the approval timeline of similar companies, such as Lepu, and their subsequent sales performance [5] - **Shareholding Changes**: Red Shirt's recent share reduction is expected to be completed soon, which may alleviate market concerns and be interpreted as a positive signal [5] - **Long-term Outlook**: The research team maintains a positive outlook on Beitaini as one of their core recommendations for 2026, emphasizing the company's potential for success [6]

Investment Rating - The investment rating for the company is "Accumulate" [5] Core Insights - The company is expected to implement a product focus and stable pricing strategy in 2025, leading to improved gross margins in the first three quarters. The main brand shows strong resilience, while the sub-brand Aikeman is experiencing breakthroughs, indicating a positive outlook for multi-brand growth to restore the company's growth momentum [2][11] - The forecast for EPS has been raised for 2025-2027 to 1.23 (+0.13), 1.56 (+0.08), and 1.90 (+0.18) yuan, respectively. A target PE of 38x for 2026 has been set, resulting in an updated target price of 59.28 yuan [11] Financial Summary - Total revenue is projected to be 5,522 million yuan in 2023, increasing to 5,736 million yuan in 2024, but decreasing to 5,479 million yuan in 2025, before rising to 6,059 million yuan in 2026 and 6,663 million yuan in 2027 [4] - Net profit attributable to the parent company is expected to decline from 757 million yuan in 2023 to 503 million yuan in 2024, with a slight recovery to 520 million yuan in 2025, and further increases to 663 million yuan in 2026 and 806 million yuan in 2027 [4] - The gross margin for the first three quarters of 2025 improved to 74.33%, a year-on-year increase of 0.6 percentage points [11] Market Performance - The company's stock price has ranged between 39.34 and 50.85 yuan over the past 52 weeks, with a total market capitalization of 20,138 million yuan [6] - The stock has shown an absolute increase of 17% over the past month, 13% over the past three months, and 18% over the past year [10] Brand Performance - The main brand, Winona, has streamlined its product series and focused on core products, achieving a ranking of 9th in the Tmall beauty industry during the Double Eleven shopping festival, maintaining its position in the top 10 for nine consecutive years [11] - The sub-brand Aikeman has seen significant growth, ranking 2nd in the Tmall beauty new brand transaction list during Double Eleven 2025, with key products achieving sales of over 100,000 units [11]